<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Capreomycin (United States and Canada: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Capreomycin (United States and Canada: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Capreomycin (United States and Canada: Not available): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11309" href="/d/html/11309.html" rel="external">see "Capreomycin (United States and Canada: Not available): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="91300" href="/d/html/91300.html" rel="external">see "Capreomycin (United States and Canada: Not available): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708654"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Clinical outcomes:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of capreomycin may be associated with worse clinical outcomes (ie, decreased effectiveness and increased mortality) compared with other parenteral therapy for pulmonary multidrug-resistant tuberculosis (MDR-TB). In patients who require parenteral treatment for pulmonary MDR-TB, reserve capreomycin for those with resistance to injectable aminoglycosides and limited treatment options.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Renal impairment:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of capreomycin in patients with renal insufficiency must be undertaken with great caution, and the risk of additional renal injury should be weighed against the benefits derived from therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Since other parenteral antituberculosis agents (streptomycin, viomycin) also have similar and sometimes irreversible toxic effects, particularly on renal function, simultaneous administration of these agents with capreomycin is not recommended. Use with other drugs (polymyxin A sulfate, colistin sulfate, amikacin, gentamicin, tobramycin, vancomycin, kanamycin, and neomycin) having nephrotoxic potential should be undertaken only with great caution.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Auditory impairment:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">The use of capreomycin in patients with preexisting auditory impairment must be undertaken with great caution, and the risk of additional cranial nerve VIII impairment should be weighed against the benefits derived from therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Since other parenteral antituberculosis agents (streptomycin, viomycin) also have similar and sometimes irreversible toxic effects, particularly on cranial nerve VIII, simultaneous administration of these agents with capreomycin is not recommended. Use with other drugs (polymyxin A sulfate, colistin sulfate, amikacin, gentamicin, tobramycin, vancomycin, kanamycin, and neomycin) having ototoxic potential should be undertaken only with great caution.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F145236"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Capastat Sulfate [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F145257"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antibiotic, Miscellaneous;</li>
<li>
                        Antitubercular Agent</li></ul></div>
<div class="block doa drugH1Div" id="F145238"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Capastat has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5ca4f8ab-6c12-48ba-81d2-a50f4fd15be0">Tuberculosis, pulmonary</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, pulmonary (alternative agent): Note:</b> Current guidelines recommend against the use of capreomycin (ATS/CDC/ERS/IDSA [Nahid 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">IM, IV: 15 mg/kg once daily <b>or</b> 25 mg/kg 3 times weekly, in combination with other appropriate agents; duration depends on clinical and microbiological response (ATS/CDC/IDSA [Nahid 2016]).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990397"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Adults:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Manufacturer's labeling (maximum: 1 g/dose):</i></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 110 mL/minute: 13.9 mg/kg every 24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 100 mL/minute: 12.7 mg/kg every 24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 80 mL/minute: 10.4 mg/kg every 24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 60 mL/minute: 8.2 mg/kg every 24 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 50 mL/minute: 7 mg/kg every 24 hours <b>or</b> 14 mg/kg every 48 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 40 mL/minute: 5.9 mg/kg every 24 hours <b>or</b> 11.7 mg/kg every 48 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 30 mL/minute: 4.7 mg/kg every 24 hours <b>or</b> 9.5 mg/kg every 48 hours <b>or</b> 14.2 mg/kg every 72 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 20 mL/minute: 3.6 mg/kg every 24 hours <b>or</b> 7.2 mg/kg every 48 hours <b>or</b> 10.7 mg/kg every 72 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 mL/minute: 2.4 mg/kg every 24 hours <b>or</b> 4.9 mg/kg every 48 hours <b>or</b> 7.3 mg/kg every 72 hours</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 0 mL/minute: 1.3 mg/kg every 24 hours <b>or</b> 2.6 mg/kg every 48 hours <b>or</b> 3.9 mg/kg every 72 hours</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Alternate dosing:</i></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: No adjustment necessary (ATS/CDC/IDSA [Nahid 2016]).</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;30 mL/minute: 15 mg/kg/dose 2 to 3 times weekly (ATS/CDC/IDSA [Nahid 2016]).</p>
<p style="text-indent:-2em;margin-left:6em;">End-stage renal disease on hemodialysis: 15 mg/kg/dose 2 to 3 times weekly; administer after hemodialysis if given on dialysis days (ATS/CDC/IDSA [Nahid 2016]).</p></div>
<div class="block doha drugH1Div" id="F50987555"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doe drugH1Div" id="F145239"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Use with caution because of the increased potential for preexisting renal dysfunction or impaired hearing. For older patients, consider giving 15 mg/kg 3 times weekly to allow for drug clearance (ATS/CDC/IDSA [Nahid 2016]).</p></div>
<div class="block dop drugH1Div" id="F145250"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="91300" href="/d/html/91300.html" rel="external">see "Capreomycin (United States and Canada: Not available): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="140b5844-c1fa-486a-a627-77ad0fc0ce2c">Tuberculosis, active, treatment; drug-resistant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tuberculosis, active, treatment; drug-resistant (alternative agent):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Current guidelines recommend against the use of capreomycin due to questionable efficacy as well as increased toxicity compared with other options. If used, it should be as part of an appropriate combination regimen; duration should be individualized based on extent of disease, rapidity of culture conversion, clinical response, and toxicity (ATS/CDC/IDSA [Nahid 2016]; ATS/CDC/ERS/IDSA [Nahid 2019]; <i>Red Book</i> [AAP 2021]; WHO 2022).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IM, IV: 15 to 30 mg/kg/dose once daily; some experts recommend an initial dose range of 15 to 20 mg/kg/dose once daily; maximum daily dose: 1,000 mg/<b>day</b>; monitor serum concentrations (ATS/CDC/IDSA [Nahid 2016]; HHS [OI pediatric] 2013; <i>Red Book</i> [AAP 2021]; Schaaf 2015; Seddon 2012).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51090241"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Drug clearance is decreased and half-life increased with decreasing renal function; specific recommendations in pediatric patients are lacking; consider dosing adjustment and frequent therapeutic drug monitoring in patients with renal impairment (ATS/CDC/IDSA [Nahid 2016]).</p></div>
<div class="block dohp drugH1Div" id="F51083888"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F145211"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hearing loss (subclinical: 11%; clinically apparent: 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrotoxicity (including increased blood urea nitrogen [36%], increased serum creatinine, renal tubular necrosis urine sedimentation abnormality)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Eosinophilia, leukocytosis, leukopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypocalcemia, hypokalemia, hypomagnesemia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (including abscess at injection site, bleeding at injection site, induration at injection site, pain at injection site)</p></div>
<div class="block coi drugH1Div" id="F145226"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to capreomycin or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F145208"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Hypocalcemia, hypokalemia, and hypomagnesemia have been reported with use. Monitor electrolytes periodically during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: May cause nephrotoxicity, including tubular necrosis, increased BUN or serum creatinine, and abnormal urinary sediment; slight elevations in BUN and serum creatinine with urinary RBCs, WBCs, and casts have been observed with prolonged treatment. Monitor renal function at baseline and periodically during treatment. A BUN &gt;30 mg/dL or other evidence of decreasing renal function should prompt clinical evaluation and dosage adjustment or therapy discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ototoxicity: May cause impairment of cranial nerve VIII, which may be irreversible; perform audiometric assessment and assessment of vestibular function prior to initiation and periodically during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Allergies: Use with caution in patients who demonstrate some form of allergy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment:<b></b> Dosage reductions are recommended for known or suspected renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878363"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In pediatric patients treated for multidrug-resistant tuberculosis, the reported incidence of hearing loss is variable (7% to 24%) with regimens that included either capreomycin or an aminoglycoside; the majority of children received amikacin compared to capreomycin; specific incidence with capreomycin not determined (Drobac 2006; Seddon 2013).</p></div>
<div class="block prod-avail drugH1Div" id="F58332964"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Capastat has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F145219"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection, as sulfate [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Capastat Sulfate: 1 g (1 ea [DSC])</p></div>
<div class="block geq drugH1Div" id="F145204"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323040"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Capastat Sulfate Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $258.54</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F145223"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">IM: Administer by deep IM injection into a large muscle mass. </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">IV: Administer over 60 minutes.</p></div>
<div class="block admp drugH1Div" id="F52612358"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Administer over 60 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Administer by deep IM injection into large muscle mass.</p></div>
<div class="block use drugH1Div" id="F145222"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Tuberculosis, pulmonary:</b> Alternative agent for the treatment of pulmonary infections caused by capreomycin-susceptible strains of <i>Mycobacterium tuberculosis</i>, in combination with other appropriate antituberculosis agents, when other agents have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli (ATS/CDC/IDSA [Nahid 2016]).</p></div>
<div class="block mst drugH1Div" id="F145264"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Capastat may be confused with Cepastat</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298954"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F145213"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: Capreomycin may enhance the neuromuscular-blocking effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colistimethate: Capreomycin may enhance the neuromuscular-blocking effect of Colistimethate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Capreomycin may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Capreomycin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymyxin B: Capreomycin may enhance the neuromuscular-blocking effect of Polymyxin B. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54927968"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Evaluate pregnancy status prior to treatment of multidrug-resistant tuberculosis in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment for multidrug-resistant tuberculosis (Esmail 2018).</p></div>
<div class="block pri drugH1Div" id="F145228"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in animal reproductions studies; the safety of capreomycin in pregnancy has not been determined.</p>
<p style="text-indent:0em;margin-top:2em;">Tuberculosis (TB) disease (active TB) is associated with adverse fetal outcomes, including intrauterine growth restriction, low birth weight, preterm birth, and perinatal death (Esmail 2018; Miele 2020), as well as adverse maternal outcomes, including increased risks for anemia and cesarean delivery. Placental transmission may rarely occur with active maternal disease (Miele 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Data are limited for use of second-line drugs during pregnancy (ie, capreomycin). The treatment of multidrug-resistant tuberculosis in pregnant patients should be individualized; evidence to support a specific regimen is not available; however, agents other than capreomycin are preferred if an injectable agent is needed (ATS/CDC/ERS/IDSA [Nahid 2019]; WHO 2020).</p></div>
<div class="block brc drugH1Div" id="F20608843"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if capreomycin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Capreomycin is not significantly absorbed when administered orally, limiting any potential exposure via breast milk. The manufacturer recommends that caution be exercised when administering capreomycin to patients who are breastfeeding. Patients with multidrug-resistant tuberculosis and a sputum smear-positive test should avoid breastfeeding when possible (Esmail 2018).</p></div>
<div class="block mop drugH1Div" id="F145217"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Audiometric measurements and vestibular function at baseline and during therapy; renal function at baseline and weekly during therapy; baseline and frequent assessment of serum electrolytes (including calcium, magnesium, and potassium), liver function tests </p></div>
<div class="block rer drugH1Div" id="F145220"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Adults: Recommended concentration for susceptibility testing: 10 mcg/mL (ATS/CDC/IDSA 2003)</p></div>
<div class="block pha drugH1Div" id="F145207"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Capreomycin is a cyclic polypeptide antimicrobial. It is administered as a mixture of capreomycin IA and capreomycin IB. The mechanism of action of capreomycin is not well understood. Mycobacterial species that have become resistant to other agents are usually still sensitive to the action of capreomycin. However, significant cross-resistance with viomycin, kanamycin, and neomycin occurs.</p></div>
<div class="block phk drugH1Div" id="F145225"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Not absorbed </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: CrCl 100 to 110 mL/minute: 5 to 6 hours; CrCl 50 to 80 mL/minute: 7 to 10 hours; CrCl 20 to 40 mL/minute: 12 to 20 hours; CrCl 10 mL/minute: 29 hours; CrCl 0 mL/minute: 55 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: IM: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (52% unchanged within 12 hours)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F145229"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Capastat</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Capastat</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Capreomycine</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Capreomycin | Caprocin sulfate</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Capastat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Capastate | Capreomycin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Capastat</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Capastat</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Capastat | Capreomycin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Capastat | Capreomycin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Capreo | Capreotec | Kapocin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Capastat</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Kapocin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Capacin | Capastat | Caprecin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Capastat | Capreomycin | Capreotec</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Capastat</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Capastat | Capreomycin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Capastat | Capreomicina</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Capastat | Capreomycin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Capastat sulfate</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Capastat</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Capastat | Capremabol | Capreomycin | Capreomycin deco | Capreomycin ferein | Capreomycin s | Capreostat | Capricyn | Kapocin | Leukocin | Lykocin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Capastat</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Capreomicin | Capreomycin | Kapocin</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Kapocin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Capastat | Kapreon</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Kapocin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AAP.2">
<a name="AAP.2"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12836625">
<a name="12836625"></a>American Thoracic Society (ATS); Centers for Disease Control (CDC); Infectious Diseases Society of America (IDSA). Treatment of tuberculosis [published correction appears in <i>MMWR Recomm Rep</i>. 2005;53(51):1203]. <i>MMWR Recomm Rep</i>. 2003;52(RR-11):1-77. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/12836625/pubmed" id="12836625" target="_blank">12836625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>. 5th ed. American College of Physicians; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Capastat.1">
<a name="Capastat.1"></a>Capastat sulfate (capreomycin for injection) [prescribing information]. Gurnee, IL: Akorn Operating Company LLC; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1379145">
<a name="1379145"></a>Davidson PT, Le HQ. Drug Treatment of Tuberculosis - 1992. <i>Drugs</i>. 1992;43(5):651-673.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/1379145/pubmed" id="1379145" target="_blank">1379145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16740844">
<a name="16740844"></a>Drobac PC, Mukherjee JS, Joseph JK, et al. Community-based therapy for children with multidrug-resistant tuberculosis.<i> Pediatrics</i>. 2006;117(6): 2022-2029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/16740844/pubmed" id="16740844" target="_blank">16740844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8412982">
<a name="8412982"></a>Drugs for Tuberculosis. <i>Med Lett Drugs Ther</i>. 1993;35(908):99-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/8412982/pubmed" id="8412982" target="_blank">8412982</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29997980">
<a name="29997980"></a>Esmail A, Sabur NF, Okpechi I, Dheda K. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. <i>J Thorac Dis</i>. 2018;10(5):3102-3118. doi:10.21037/jtd.2018.05.11<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/29997980/pubmed" id="29997980" target="_blank">29997980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8350889">
<a name="8350889"></a>Iseman MD. Treatment of Multidrug-Resistant Tuberculosis. <i>N Engl J Med</i>. 1993;329(11):784-791.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/8350889/pubmed" id="8350889" target="_blank">8350889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2462388">
<a name="2462388"></a>Lehmann CR, Garrett LE, Winn RE, et al. Capreomycin Kinetics in Renal Impairment and Clearance by Hemodialysis. <i>Am Rev Respir Dis</i>. 1988;138(5):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/2462388/pubmed" id="2462388" target="_blank">2462388</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32459437">
<a name="32459437"></a>Miele K, Bamrah Morris S, Tepper NK. Tuberculosis in pregnancy. <i>Obstet Gynecol</i>. 2020;135(6):1444-1453. doi:10.1097/AOG.0000000000003890<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/32459437/pubmed" id="32459437" target="_blank">32459437</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27516382">
<a name="27516382"></a>Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-195. doi:10.1093/cid/ciw376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/27516382/pubmed" id="27516382" target="_blank">27516382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31729908">
<a name="31729908"></a>Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. <i>Am J Respir Crit Care Med</i>. 2019;200(10):e93-e142. doi:10.1164/rccm.201909-1874ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/31729908/pubmed" id="31729908" target="_blank">31729908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12381217">
<a name="12381217"></a>Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. <i>Drugs</i>. 2002;62(15):2169-2183. doi:10.2165/00003495-200262150-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/12381217/pubmed" id="12381217" target="_blank">12381217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26095192">
<a name="26095192"></a>Schaaf HS, Garcia-Prats AJ, Donald PR. Antituberculosis drugs in children. <i>Clin Pharmacol Ther</i>. 2015;98(3):252-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/26095192/pubmed" id="26095192" target="_blank">26095192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22983960">
<a name="22983960"></a>Seddon JA, Furin JJ, Gale M, et al. Caring for children with drug-resistant tuberculosis- practice-based recommendations. <i>Am J Respir Crit Care Med</i>. 2012;186:953-964.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/22983960/pubmed" id="22983960" target="_blank">22983960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22960077">
<a name="22960077"></a>Seddon JA, Thee S, Jacobs K, et al. Hearing loss in children treated for multi-drug resistant tuberculosis. <i>J Infect</i>. 2013;66:320-3299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/capreomycin-united-states-and-canada-not-available-drug-information/abstract-text/22960077/pubmed" id="22960077" target="_blank">22960077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-opportunistic-infection/whats-new</a>. Updated November 6, 2013. Accessed February 17, 2023.</div>
</li>
<li>
<div class="reference">
<i>WHO operational handbook on tuberculosis. Module 5: management of tuberculosis in children and adolescents</i>. Geneva: World Health Organization; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment. https://www.who.int/publications/i/item/9789240007048. Published 2020.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9194 Version 169.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
